Amgen Inc.
Amgen Reports First Quarter 2024 Financial Results
Summary
Amgen Inc. announced its first quarter 2024 financial results, showing total revenues of $7.4 billion, a 22% increase from the prior year. Product sales rose by 22%, driven by 25% volume growth, with notable contributions from several key products including Repatha, Prolia, and TEZSPIRE. However, GAAP net loss per share was $0.21 due to a mark-to-market loss on an equity investment and higher operating expenses. Non-GAAP net income per share was $3.96, reflecting the underlying operational performance of the company.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement